Hayward (NYSE:HAYW) Given New $12.00 Price Target at The Goldman Sachs Group
Hayward (NYSE:HAYW – Free Report) had its price objective decreased by The Goldman Sachs Group from $13.50 to $12.00 in a research report released on Wednesday, Benzinga reports. The Goldman Sachs Group currently has a neutral rating on the stock. A number of other equities analysts have also weighed in on HAYW. KeyCorp cut their […]
More Stories
Analyzing Simulations Plus (NASDAQ:SLP) and Veea (NASDAQ:VEEA)
Veea (NASDAQ:VEEA – Get Free Report) and Simulations Plus (NASDAQ:SLP – Get Free Report) are both small-cap computer and technology...
Rugby Resources (CVE:RUG) Shares Down 25% – Time to Sell?
Rugby Resources Ltd. (CVE:RUG – Get Free Report) shares traded down 25% on Tuesday . The company traded as low...
Milos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) insider Milos Miljkovic sold 932 shares of the business’s stock in a...
Insider Selling: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Sells 4,028 Shares of Stock
Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Get Free Report) CFO Blaine Davis sold 4,028 shares of the business’s stock in a...
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CFO Kenneth Allen Myszkowski Sells 27,167 Shares
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) CFO Kenneth Allen Myszkowski sold 27,167 shares of the company’s stock in...
Bowen Acquisition Corp Adjourns Extraordinary Meeting to Discuss Extension Proposal
Bowen Acquisition Corp (NASDAQ:BOWNU) recently adjourned its extraordinary general meeting, initially scheduled for January 7, 2025. The purpose of the...